{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:10:01Z","timestamp":1787328601511,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immune checkpoint inhibitors (ICIs) are promising for leptomeningeal disease (LMD), but systemic delivery is limited by poor cerebrospinal fluid penetration and treatment-related toxicity. This study evaluates the safety and efficacy of adjunctive intrathecal (IT) ICI therapy compared with systemic ICI alone.\u00a0We report two institutional cases of melanoma-associated LMD treated with IT ICI alongside systemic therapy. Following PRISMA guidelines, PubMed, Embase, and Scopus were systematically reviewed, identifying 28 eligible studies consisting of case reports, small series, and early phase trials. Of 542 patients screened, 201 received ICI therapy: 161 systemic ICI alone and 40 IT ICI with concurrent systemic therapy. Patient-level and aggregate data were extracted to compare adverse events (AEs), progression-free survival (PFS), and overall survival (OS). Exploratory time- and dose-adjusted analyses accounted for differences in treatment exposure.\u00a0IT ICI therapy demonstrated a favorable safety profile. At the patient level, adjunct IT delivery was associated with a non-significant trend toward reduced grade\u2009\u2265\u20093 AE risk (RR 0.50; 95% CI, 0.22\u20131.13;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.096). At the event level, adjunct IT therapy was significantly associated with 72% fewer grade\u2009\u2265\u20093 AEs per patient (rate ratio 0.28; 95% CI, 0.12\u20130.64;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003). Dose-adjusted meta-regression suggested cumulative exposure did not explain these differences. No significant differences were observed in PFS or OS after multivariable adjustment.\u00a0Adjunct IT ICI therapy was not associated with increased adverse event risk or high-grade toxicity burden compared with systemic ICI alone, supporting its feasibility as an adjunctive therapeutic strategy for LMD that warrants prospective evaluation.\n                  <\/jats:p>","DOI":"10.1007\/s10143-026-04454-z","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T02:38:12Z","timestamp":1787279892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intrathecal immune checkpoint inhibitors as adjunctive therapy for leptomeningeal disease: A case series and systematic review"],"prefix":"10.1007","volume":"49","author":[{"given":"Manav","family":"Daftari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian K.","family":"Ramsoomair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Aka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vratko","family":"Himic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela Aramburu","family":"Berckemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Chandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaidya","family":"Govindrajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Lutzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Ivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo J.","family":"Komotar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruham","family":"Nasany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"1","key":"4454_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/1097-0142(19830101)51:1<154::aid-cncr2820510130>3.0.co;2-k","volume":"51","author":"CP Kokkoris","year":"1983","unstructured":"Kokkoris CP (1983) Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid? Cancer 51(1):154\u2013160. https:\/\/doi.org\/10.1002\/1097-0142(19830101)51:1%3C154::aid-cncr2820510130%3E3.0.co;2-k","journal-title":"Cancer"},{"issue":"10","key":"4454_CR2","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1093\/neuonc\/noae103","volume":"26","author":"JA Wilcox","year":"2024","unstructured":"Wilcox JA, Chukwueke UN, Ahn MJ, Aizer AA, Bale TA, Brandsma D et al (2024) Leptomeningeal metastases from solid tumors: a society for neuro-oncology and american society of clinical oncology consensus review on clinical management and future directions. Neuro Oncol 26(10):1781\u20131804. https:\/\/doi.org\/10.1093\/neuonc\/noae103","journal-title":"Neuro Oncol"},{"key":"4454_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/B978-0-12-811161-1.00013-X","volume":"149","author":"S Taillibert","year":"2018","unstructured":"Taillibert S, Chamberlain MC (2018) Leptomeningeal metastasis. Handb Clin Neurol 149:169\u2013204. https:\/\/doi.org\/10.1016\/B978-0-12-811161-1.00013-X","journal-title":"Handb Clin Neurol"},{"issue":"42","key":"4454_CR4","doi-asserted-by":"publisher","first-page":"73312","DOI":"10.18632\/oncotarget.20272","volume":"8","author":"G Nayar","year":"2017","unstructured":"Nayar G, Ejikeme T, Chongsathidkiet P, Elsamadicy AA, Blackwell KL, Clarke JM et al (2017) Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget 8(42):73312\u201373328. https:\/\/doi.org\/10.18632\/oncotarget.20272","journal-title":"Oncotarget"},{"issue":"Suppl 5","key":"4454_CR5","doi-asserted-by":"publisher","first-page":"v86","DOI":"10.1093\/noajnl\/vdab108","volume":"3","author":"U Sener","year":"2021","unstructured":"Sener U, Kumthekar P, Boire A (2021) Advances in the diagnosis, evaluation, and management of leptomeningeal disease. Neurooncol Adv 3(Suppl 5):v86\u2013v95. https:\/\/doi.org\/10.1093\/noajnl\/vdab108","journal-title":"Neurooncol Adv"},{"issue":"8","key":"4454_CR6","doi-asserted-by":"publisher","first-page":"e2225459","DOI":"10.1001\/jamanetworkopen.2022.25459","volume":"5","author":"N Lamba","year":"2022","unstructured":"Lamba N, Ott PA, Iorgulescu JB (2022) Use of first-line immune checkpoint inhibitors and association with overall survival among patients with metastatic melanoma in the Anti-PD-1 Era. JAMA Netw Open 5(8):e2225459. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.25459","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4454_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3892\/ol.2024.14775","volume":"29","author":"X Qian","year":"2025","unstructured":"Qian X, Tao Y, Chen H, Li X, Wang Y, Xu X et al (2025) Real\u2013world evaluation of the efficacy of immune checkpoint inhibitors in the treatment of metastatic breast cancer. Oncol Lett 29(1):29. https:\/\/doi.org\/10.3892\/ol.2024.14775","journal-title":"Oncol Lett"},{"key":"4454_CR8","doi-asserted-by":"publisher","first-page":"955440","DOI":"10.3389\/fonc.2022.955440","volume":"12","author":"F Yang","year":"2022","unstructured":"Yang F, Wang Y, Tang L, Mansfield AS, Adjei AA, Leventakos K et al (2022) Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. Front Oncol 12:955440. https:\/\/doi.org\/10.3389\/fonc.2022.955440","journal-title":"Front Oncol"},{"issue":"1","key":"4454_CR9","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/s41598-024-52034-2","volume":"14","author":"J Feng","year":"2024","unstructured":"Feng J, Chen X, Wei J, Weng Y, Wang J, Wang T et al (2024) Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study. Sci Rep 14(1):2315. https:\/\/doi.org\/10.1038\/s41598-024-52034-2","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"4454_CR10","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","volume":"24","author":"L Xia","year":"2019","unstructured":"Xia L, Liu Y, Wang Y (2019) PD-1\/PD-L1 Blockade therapy in advanced non-small-cell lung cancer: current status and future directions. Oncologist 24(Suppl 1):S31\u2013S41. https:\/\/doi.org\/10.1634\/theoncologist.2019-IO-S1-s05","journal-title":"Oncologist"},{"issue":"6","key":"4454_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s11912-025-01676-0","volume":"27","author":"L Kong","year":"2025","unstructured":"Kong L, Yiu CH, Lu CY (2025) Effectiveness and safety of immune checkpoint inhibitors in colorectal cancer: a systematic review of real-world studies. Curr Oncol Rep 27(6):687\u2013702. https:\/\/doi.org\/10.1007\/s11912-025-01676-0","journal-title":"Curr Oncol Rep"},{"issue":"10304","key":"4454_CR12","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV (2021) Immune checkpoint inhibitors in melanoma. Lancet 398(10304):1002\u20131014. https:\/\/doi.org\/10.1016\/S0140-6736(21)01206-X","journal-title":"Lancet"},{"key":"4454_CR13","doi-asserted-by":"publisher","first-page":"114949","DOI":"10.1016\/j.addr.2023.114949","volume":"199","author":"R Ajeeb","year":"2023","unstructured":"Ajeeb R, Clegg JR (2023) Intrathecal delivery of macromolecules: clinical status and emerging technologies. Adv Drug Deliv Rev 199:114949. https:\/\/doi.org\/10.1016\/j.addr.2023.114949","journal-title":"Adv Drug Deliv Rev"},{"key":"4454_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060824","author":"S Triarico","year":"2019","unstructured":"Triarico S, Maurizi P, Mastrangelo S, Attina G, Capozza MA, Ruggiero A (2019) Improving the brain delivery of chemotherapeutic drugs in childhood brain tumors. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers11060824","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4454_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12885-019-5741-y","volume":"19","author":"MTJ van Bussel","year":"2019","unstructured":"van Bussel MTJ, Beijnen JH, Brandsma D (2019) Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. BMC Cancer 19(1):519. https:\/\/doi.org\/10.1186\/s12885-019-5741-y","journal-title":"BMC Cancer"},{"issue":"9","key":"4454_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11095-018-2455-9","volume":"35","author":"M Kim","year":"2018","unstructured":"Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN et al (2018) Barriers to effective drug treatment for brain metastases: a multifactorial problem in the delivery of precision medicine. Pharm Res 35(9):177. https:\/\/doi.org\/10.1007\/s11095-018-2455-9","journal-title":"Pharm Res"},{"key":"4454_CR17","doi-asserted-by":"publisher","first-page":"114824","DOI":"10.1016\/j.biopha.2023.114824","volume":"163","author":"K Mortezaee","year":"2023","unstructured":"Mortezaee K, Majidpoor J (2023) Mechanisms of CD8(+) T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1. Biomed Pharmacother 163:114824. https:\/\/doi.org\/10.1016\/j.biopha.2023.114824","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"4454_CR18","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/oncolo\/oyac064","volume":"27","author":"I Schlam","year":"2022","unstructured":"Schlam I, Gatti-Mays ME (2022) Immune checkpoint inhibitors in the treatment of breast cancer brain metastases. Oncologist 27(7):538\u2013547. https:\/\/doi.org\/10.1093\/oncolo\/oyac064","journal-title":"Oncologist"},{"issue":"6","key":"4454_CR19","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1007\/s13311-022-01261-4","volume":"19","author":"JA Wilcox","year":"2022","unstructured":"Wilcox JA, Li MJ, Boire AA (2022) Leptomeningeal metastases: new opportunities in the modern era. Neurotherapeutics 19(6):1782\u20131798. https:\/\/doi.org\/10.1007\/s13311-022-01261-4","journal-title":"Neurotherapeutics"},{"issue":"7","key":"4454_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11910-022-01198-3","volume":"22","author":"A Sharma","year":"2022","unstructured":"Sharma A, Low JT, Kumthekar P (2022) Advances in the diagnosis and treatment of leptomeningeal disease. Curr Neurol Neurosci Rep 22(7):413\u2013425. https:\/\/doi.org\/10.1007\/s11910-022-01198-3","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"10","key":"4454_CR21","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/jbisrir-d-19-00099","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synthesis 18(10):2127\u20132133. https:\/\/doi.org\/10.11124\/jbisrir-d-19-00099","journal-title":"JBI Evid Synthesis"},{"key":"4454_CR22","unstructured":"JBI (2021) Checklist for case reports. https:\/\/jbi.global\/sites\/default\/files\/2021-10\/Checklist_for_Case_Reports.docx Accessed"},{"issue":"9","key":"4454_CR23","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73(9):712\u2013716. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x","journal-title":"ANZ J Surg"},{"key":"4454_CR24","unstructured":"Group R-IVD (2025) Risk Of Bias. Non-randomized Studies - of Interventions, Version 2 (ROBINS-I V2). ROBINS-I V2 tool. Risk of Bias Tools"},{"issue":"2","key":"4454_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.nec.2018.12.010","volume":"30","author":"VV Sukul","year":"2019","unstructured":"Sukul VV (2019) Intrathecal pain therapy for the management of chronic noncancer pain. Neurosurg Clin N Am 30(2):195\u2013201. https:\/\/doi.org\/10.1016\/j.nec.2018.12.010","journal-title":"Neurosurg Clin N Am"},{"key":"4454_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00190-19","author":"R Nau","year":"2020","unstructured":"Nau R, Blei C, Eiffert H (2020) Intrathecal antibacterial and antifungal therapies. Clin Microbiol Rev. https:\/\/doi.org\/10.1128\/CMR.00190-19","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"4454_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11060-024-04582-w","volume":"167","author":"E Singh","year":"2024","unstructured":"Singh E, Gurses ME, Costello MC, Berke C, Lu VM, Daggubati L et al (2024) Intrathecal chemotherapy for leptomeningeal disease in high-grade gliomas: a systematic review. J Neurooncol 167(1):39\u201347. https:\/\/doi.org\/10.1007\/s11060-024-04582-w","journal-title":"J Neurooncol"},{"issue":"19","key":"4454_CR28","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.2174\/0929867330666230508142657","volume":"31","author":"F Jafari","year":"2024","unstructured":"Jafari F, Nodeh MM, Hosseinjani H, Baharara H, Azad S, Arasteh O et al (2024) A review on the efficacy and safety of intrathecal administration of novel medications for leptomeningeal metastases in solid cancers. Curr Med Chem 31(19):2732\u20132750. https:\/\/doi.org\/10.2174\/0929867330666230508142657","journal-title":"Curr Med Chem"},{"issue":"6","key":"4454_CR29","doi-asserted-by":"publisher","first-page":"572","DOI":"10.4048\/jbc.2023.26.e40","volume":"26","author":"D Dupoiron","year":"2023","unstructured":"Dupoiron D, Autier L, Lebrec N, Seegers V, Folliard C, Patsouris A et al (2023) Intrathecal catheter for chemotherapy in leptomeningeal carcinomatosis from her2-negative metastatic breast cancer. J Breast Cancer 26(6):572\u2013581. https:\/\/doi.org\/10.4048\/jbc.2023.26.e40","journal-title":"J Breast Cancer"},{"issue":"5","key":"4454_CR30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1182\/blood.V51.5.835.835","volume":"51","author":"WA Bleyer","year":"1978","unstructured":"Bleyer WA, Poplack DG, Simon RM (1978) Concentration x time methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood 51(5):835\u2013842","journal-title":"Blood"},{"issue":"2","key":"4454_CR31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/(sici)1097-0142(19990115)85:2<511::aid-cncr33>3.0.co;2-h","volume":"85","author":"AM Moser","year":"1999","unstructured":"Moser AM, Adamson PC, Gillespie AJ, Poplack DG, Balis FM (1999) Intraventricular concentration times time (C x T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma. Cancer 85(2):511\u2013516. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19990115)85:2%3C511::aid-cncr33%3E3.0.co;2-h","journal-title":"Cancer"},{"issue":"4","key":"4454_CR32","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","volume":"29","author":"IC Glitza Oliva","year":"2023","unstructured":"Glitza Oliva IC, Ferguson SD, Bassett R Jr., Foster AP, John I, Hennegan TD et al (2023) Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med 29(4):898\u2013905. https:\/\/doi.org\/10.1038\/s41591-022-02170-x","journal-title":"Nat Med"},{"issue":"3","key":"4454_CR33","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s11060-024-04843-8","volume":"170","author":"J Zhen","year":"2024","unstructured":"Zhen J, Chen L, Wang H, Li D, Lai M, Ding Y et al (2024) Intrathecal anti-PD-1 treatment in metastatic melanoma patients with leptomeningeal disease (LMD): real-world data and evidence. J Neurooncol 170(3):665\u2013673. https:\/\/doi.org\/10.1007\/s11060-024-04843-8","journal-title":"J Neurooncol"},{"key":"4454_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17081263","author":"GY Lee","year":"2025","unstructured":"Lee GY, Glicksman MA, Patel R, Malhotra S, Moelis N, Vanjani NN et al (2025) Retrospective review of intra-cerebrospinal fluid (CSF) drug delivery in CNS malignancies: safety, clinical efficacy and pharmacokinetic profiles of intracerebroventricular (ICV), lumbar intrathecal (LIT), and intra-cisterna magna (ICM) injections. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17081263","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4454_CR35","first-page":"1536","volume":"11","author":"T Fujimoto","year":"1984","unstructured":"Fujimoto T (1984) [Pharmacokinetics of intrathecal chemotherapy and clinical problems]. Gan Kagaku Ryoho 11(8):1536\u20131542","journal-title":"Gan Kagaku Ryoho"},{"issue":"5","key":"4454_CR36","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00228-024-03647-z","volume":"80","author":"C Oliveira","year":"2024","unstructured":"Oliveira C, Mainoli B, Duarte GS, Machado T, Tinoco RG, Esperanca-Martins M et al (2024) Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis. Eur J Clin Pharmacol 80(5):677\u2013684. https:\/\/doi.org\/10.1007\/s00228-024-03647-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"4454_CR37","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"issue":"1","key":"4454_CR38","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.4110\/in.2020.20.e9","volume":"20","author":"J Choi","year":"2020","unstructured":"Choi J, Lee SY (2020) Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw 20(1):e9. https:\/\/doi.org\/10.4110\/in.2020.20.e9","journal-title":"Immune Netw"},{"issue":"36","key":"4454_CR39","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"issue":"2","key":"4454_CR40","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1212\/WNL.0000000000012122","volume":"97","author":"V Nersesjan","year":"2021","unstructured":"Nersesjan V, McWilliam O, Krarup LH, Kondziella D (2021) Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: a systematic review. Neurology 97(2):e191\u2013e202. https:\/\/doi.org\/10.1212\/WNL.0000000000012122","journal-title":"Neurology"},{"issue":"7","key":"4454_CR41","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","volume":"78","author":"R Velasco","year":"2021","unstructured":"Velasco R, Villagran M, Jove M, Simo M, Vilarino N, Alemany M et al (2021) Encephalitis induced by immune checkpoint inhibitors: a systematic review. JAMA Neurol 78(7):864\u2013873. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0249","journal-title":"JAMA Neurol"},{"issue":"9","key":"4454_CR42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S1470-2045(10)70034-6","volume":"11","author":"P Beauchesne","year":"2010","unstructured":"Beauchesne P (2010) Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 11(9):871\u2013879. https:\/\/doi.org\/10.1016\/S1470-2045(10)70034-6","journal-title":"Lancet Oncol"},{"issue":"9","key":"4454_CR43","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","volume":"22","author":"JA Thompson","year":"2024","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Zaid MA, Achufusi A, Armand P et al (2024) NCCN guidelines(R) insights: management of immunotherapy-related toxicities, version 2.2024. J Natl Compr Canc Netw 22(9):582\u2013592. https:\/\/doi.org\/10.6004\/jnccn.2024.0057","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"4454_CR44","doi-asserted-by":"publisher","first-page":"34352","DOI":"10.1038\/s41598-025-16889-3","volume":"15","author":"RA Guerrieri","year":"2025","unstructured":"Guerrieri RA, Fischer GM, Cortez JR, Knighton BG, Ledesma DA, Hudgens CW et al (2025) Preclinical models of melanoma leptomeningeal disease to assess intrathecal checkpoint blockade. Sci Rep 15(1):34352. https:\/\/doi.org\/10.1038\/s41598-025-16889-3","journal-title":"Sci Rep"},{"issue":"12","key":"4454_CR45","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1001\/jamaoncol.2020.4508","volume":"6","author":"J Portnow","year":"2020","unstructured":"Portnow J, Wang D, Blanchard MS, Tran V, Alizadeh D, Starr R et al (2020) Systemic anti-PD-1 immunotherapy results in PD-1 blockade on t cells in the cerebrospinal fluid. JAMA Oncol 6(12):1947\u20131951. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4508","journal-title":"JAMA Oncol"},{"issue":"2","key":"4454_CR46","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/apjon.apjon_3_19","volume":"6","author":"S Trinh","year":"2019","unstructured":"Trinh S, Le A, Gowani S, La-Beck NM (2019) Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines. Asia Pac J Oncol Nurs 6(2):154\u2013160. https:\/\/doi.org\/10.4103\/apjon.apjon_3_19","journal-title":"Asia Pac J Oncol Nurs"},{"key":"4454_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139\u2013148. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016","journal-title":"Eur J Cancer"},{"key":"4454_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153575","author":"Y Lao","year":"2022","unstructured":"Lao Y, Shen D, Zhang W, He R, Jiang M (2022) Immune checkpoint inhibitors in cancer therapy-how to overcome drug resistance? Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14153575","journal-title":"Cancers (Basel)"},{"key":"4454_CR49","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jpba.2018.10.025","volume":"164","author":"D Pluim","year":"2019","unstructured":"Pluim D, Ros W, van Bussel MTJ, Brandsma D, Beijnen JH, Schellens JHM (2019) Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. J Pharm Biomed Anal 164:128\u2013134. https:\/\/doi.org\/10.1016\/j.jpba.2018.10.025","journal-title":"J Pharm Biomed Anal"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04454-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-026-04454-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04454-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T15:02:38Z","timestamp":1787324558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-026-04454-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4454"],"URL":"https:\/\/doi.org\/10.1007\/s10143-026-04454-z","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"2 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board at the University of Miami prior to the retrospective chart review of two patients. The requirement for informed consent was waived by the Institutional Review Board due to the retrospective nature of the study and the use of de-identified data.","order":1,"name":"Ethics","label":"<b>Ethics approval and consent to participate<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I would like to declare on behalf of my coauthors that the work described is original research that has not been published previously and is not under consideration for publication elsewhere, in whole or in part. All the authors listed have approved the uploaded manuscript.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was a retrospective analysis; therefore, a clinical trial registration number is not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"531"}}